Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells

<table>Focused synergy maps compiling combination index (CI) values. The CI values were determined with a narrower dose area with <svg height="10.925" id="M125" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 33.974998 10.925" width="33.974998" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,0,0,-.017,.062,10.65)"><path d="M447 623l8 -12l-283 -613l-74 -10l-7 11q174 283 297 551h-216q-48 0 -62.5 -12t-33.5 -63h-29q10 60 18 148h382z" id="x37"></path></g><g transform="matrix(.017,0,0,-.017,11.996,10.65)"><path d="M528 54l-36 -38l-198 201l-198 -201l-36 38l197 200l-197 201l36 38l198 -202l198 202l36 -38l-197 -201z" id="xD7"></path></g><g transform="matrix(.017,0,0,-.017,25.748,10.65)"><path d="M447 623l8 -12l-283 -613l-74 -10l-7 11q174 283 297 551h-216q-48 0 -62.5 -12t-33.5 -63h-29q10 60 18 148h382z" id="x37"></path></g>
</svg> drug combination design. Drug antagonism (red), additivity (yellow), and synergism (green) were determined for PC3 and DU145 cells exposed to <svg height="11.6875" id="M126" style="vertical-align:-0.20473pt" version="1.1" viewbox="0 0 37.237499 11.6875" width="37.237499" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,0,0,-.017,.062,11.363)"><path d="M43 650h280q194 0 282 -85q85 -82 85 -215q0 -173 -123 -267q-107 -83 -297 -83h-236v27q65 5 79.5 19.5t14.5 77.5v402q0 45 -6 62.5t-21.5 24t-57.5 9.5v28zM213 547v-416q0 -55 24.5 -75t81.5 -20q133 0 203 86t70 214q0 80 -30 143t-88 97q-66 41 -170 41
q-62 0 -78 -13q-13 -9 -13 -57z" id="x44"></path></g><g transform="matrix(.017,0,0,-.017,12.846,11.363)"><path d="M381 665q131 0 226.5 -93t95.5 -239q0 -158 -96 -253t-238 -95q-137 0 -231 95t-94 238q0 142 92.5 244.5t244.5 102.5zM359 629q-89 0 -151 -74.5t-62 -208.5q0 -141 69 -233t175 -92q90 0 150.5 74t60.5 211q0 152 -69 237.5t-173 85.5z" id="x4F"></path></g><g transform="matrix(.017,0,0,-.017,25.85,11.363)"><path d="M614 175l29 -10q-33 -109 -57 -154q-121 -26 -184 -26q-90 0 -160.5 29t-112.5 77t-63.5 105.5t-21.5 119.5q0 157 108 253t277 96q36 0 71.5 -5t69 -13.5t36.5 -8.5q15 -102 20 -150l-29 -8q-20 79 -66.5 114t-128.5 35q-119 0 -187.5 -86t-68.5 -207
q0 -140 73.5 -227.5t188.5 -87.5q73 0 119.5 37.5t86.5 116.5z" id="x43"></path></g>
</svg> and <svg height="11.6875" id="M127" style="vertical-align:-0.20473pt" version="1.1" viewbox="0 0 36.25 11.6875" width="36.25" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,0,0,-.017,.062,11.363)"><path d="M43 650h280q194 0 282 -85q85 -82 85 -215q0 -173 -123 -267q-107 -83 -297 -83h-236v27q65 5 79.5 19.5t14.5 77.5v402q0 45 -6 62.5t-21.5 24t-57.5 9.5v28zM213 547v-416q0 -55 24.5 -75t81.5 -20q133 0 203 86t70 214q0 80 -30 143t-88 97q-66 41 -170 41
q-62 0 -78 -13q-13 -9 -13 -57z" id="x44"></path></g><g transform="matrix(.017,0,0,-.017,12.846,11.363)"><path d="M381 665q131 0 226.5 -93t95.5 -239q0 -158 -96 -253t-238 -95q-137 0 -231 95t-94 238q0 142 92.5 244.5t244.5 102.5zM359 629q-89 0 -151 -74.5t-62 -208.5q0 -141 69 -233t175 -92q90 0 150.5 74t60.5 211q0 152 -69 237.5t-173 85.5z" id="x4F"></path></g><g transform="matrix(.017,0,0,-.017,25.068,11.363)"><path d="M655 0h-263v28q46 5 55.5 14.5t-5.5 34.5l-132 214q-69 -104 -122 -202q-19 -32 -10.5 -43.5t58.5 -17.5v-28h-229v28q44 5 70 17t47 40q47 59 164 239l-134 214q-33 50 -54 64t-74 20v28h246v-28q-44 -5 -52 -14t5 -28q32 -55 114 -182q66 102 99 162q19 33 10.5 44.5
t-57.5 17.5v28h228v-28q-56 -6 -80 -19.5t-58 -57.5q-45 -62 -121 -179l157 -246q35 -53 60.5 -70t77.5 -22v-28z" id="x58"></path></g>
</svg> for 72 hours.</table>

Biochemistry Research International

fig5

Figure 5

Figure 5: Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells 